← Leaderboards
Karen L Cropsey
Virginia Commonwealth University
$11,314,574
Attributed
$17,657,707
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,361,593 · 12
By mechanism
R01$13,567,693 · 5
P01$6,342,959 · 3
U01$1,821,912 · 1
R34$668,250 · 1
K23$632,008 · 1
R21$328,771 · 1
Top collaborators
- Karen L Gamble9 shared
- Heidi M. Crane6 shared
- Conall Michael O'Cleirigh6 shared
- Michael Jeffrey Vinikoor6 shared
- Michael J Mugavero5 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Carolyn J. Heckman$10,065,963
- Maghboeba Mosavel$2,075,080
- Jessica Gokee Larose$6,023,004
- Xiangning Chen$3,778,236
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantSmoking CessationSmokingReportingUnited StatesAlcoholsCommunitiesResearch PersonnelProgramsCessation Of LifeGeneral PopulationTrainingSmokerNicotine DependenceComorbidityAdultPreventionAlcohol ConsumptionClinicCaringMortalityPharmaceutical PreparationsResourcesCharacteristics
Grant awards (52)
Medications for opioid use disorder differentially modulate intrinsically photosensitive retinal ganglion cell function, sleep, and circadian rhythms: implications for treatment$1,098,863
R01 · FY2025 · DA · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,028,772
P01 · FY2025 · AA · contact PI
Admin Core$205,755
P01 · FY2025 · AA · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$86,160
P01 · FY2025 · AA · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,131,143
P01 · FY2024 · AA · contact PI
Medications for opioid use disorder differentially modulate intrinsically photosensitive retinal ganglion cell function, sleep, and circadian rhythms: implications for treatment$1,098,863
R01 · FY2024 · DA · contact PI
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal$536,155
R01 · FY2024 · DA · contact PI
Admin Core$102,675
P01 · FY2024 · AA · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,143,049
P01 · FY2023 · AA · contact PI
Medications for opioid use disorder differentially modulate intrinsically photosensitive retinal ganglion cell function, sleep, and circadian rhythms: implications for treatment$1,106,050
R01 · FY2023 · DA · contact PI
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal$554,708
R01 · FY2023 · DA · contact PI
Admin Core$102,526
P01 · FY2023 · AA · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,137,273
P01 · FY2022 · AA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$721,940
R01 · FY2022 · DA · contact PI
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal$544,353
R01 · FY2022 · DA · contact PI
Admin Core$102,395
P01 · FY2022 · AA · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,177,489
P01 · FY2021 · AA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$658,700
R01 · FY2021 · DA · contact PI
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal$547,692
R01 · FY2021 · DA · contact PI
Admin Core$125,722
P01 · FY2021 · AA · contact PI
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal$58,055
R01 · FY2021 · DA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$661,921
R01 · FY2020 · DA · contact PI
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal$596,233
R01 · FY2020 · DA · contact PI
In Vivo Experience with NRT to Increase Adherence and Smoking Abstinence$513,930
R01 · FY2020 · DA · contact PI
3/3 Alcohol Research Consortium in HIV - Intervention Research Arm (ARCH-IRA)$347,377
U01 · FY2020 · AA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$97,064
R01 · FY2020 · DA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$661,628
R01 · FY2019 · DA · contact PI
In Vivo Experience with NRT to Increase Adherence and Smoking Abstinence$513,930
R01 · FY2019 · DA · contact PI
3/3 Alcohol Research Consortium in HIV â Intervention Research Arm (ARCH-IRA)$340,037
U01 · FY2019 · AA · contact PI
NRT sampling and selection to Increase Medication Adherence$222,750
R34 · FY2019 · DA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$741,283
R01 · FY2018 · DA · contact PI
In Vivo Experience with NRT to Increase Adherence and Smoking Abstinence$513,930
R01 · FY2018 · DA · contact PI
3/3 Alcohol Research Consortium in HIV â Intervention Research Arm (ARCH-IRA)$369,768
U01 · FY2018 · AA · contact PI
NRT sampling and selection to Increase Medication Adherence$222,750
R34 · FY2018 · DA · contact PI
In Vivo Experience with NRT to Increase Adherence and Smoking Abstinence$513,930
R01 · FY2017 · DA · contact PI
3/3 Alcohol Research Consortium in HIV â Intervention Research Arm (ARCH-IRA)$368,340
U01 · FY2017 · AA · contact PI
NRT sampling and selection to Increase Medication Adherence$222,750
R34 · FY2017 · DA · contact PI
In Vivo Experience with NRT to Increase Adherence and Smoking Abstinence$513,930
R01 · FY2016 · DA · contact PI
3/3 Alcohol Research Consortium in HIV â Intervention Research Arm (ARCH-IRA)$396,390
U01 · FY2016 · AA · contact PI
Integrated Smoking Cessation Treatment for Low Income Community Corrections$247,041
R01 · FY2013 · CA · contact PI
Integrated Smoking Cessation Treatment for Low Income Community Corrections$262,809
R01 · FY2012 · CA · contact PI
Integrated Smoking Cessation Treatment for Low Income Community Corrections$262,809
R01 · FY2011 · CA · contact PI
Integrated Smoking Cessation Treatment for Low Income Community Corrections$270,938
R01 · FY2010 · CA · contact PI
Integrated Smoking Cessation Treatment for Low Income Community Corrections$270,938
R01 · FY2009 · CA · contact PI
Relapse prevention to reduce HIV among women prisoners$147,796
R21 · FY2008 · DA · contact PI
Relapse prevention to reduce HIV among women prisoners$180,975
R21 · FY2007 · DA · contact PI
Smoking Research With Incarcerated Females$81,416
K23 · FY2006 · DA · contact PI
Smoking Research With Incarcerated Females$52,661
K23 · FY2006 · DA · contact PI
Smoking Research With Incarcerated Females$139,147
K23 · FY2005 · DA
Smoking Research With Incarcerated Females$119,836
K23 · FY2004 · DA
Smoking Research With Incarcerated Females$119,474
K23 · FY2003 · DA
Smoking Research With Incarcerated Females$119,474
K23 · FY2002 · DA